We are developing generative AI to support decision-making for healthcare professionals and the general public. Specifically, Cubec functions as a learning support tool that answers questions arising in physicians’ daily practice, and it generates revenue by providing pharmaceutical companies with high-precision data on physician needs. We are planning a phased business rollout, with the ultimate goal of implementing as a Software as a Medical Device (SaMD) that supports physicians’ clinical decision-making.
医師向け臨床ナレッジAI「Cubec」を開発する株式会社Cubec（本社：大阪府吹田市、代表取締役CEO：奥井 伸輔）は、2026年2月に「Cubec」のシステムアップデートを実施し、「高速・推論・論文」の3モードを搭載しま...
[画像1: https://prtimes.jp/i/124652/7/resize/d124652-7-ba24ae8e703572f504f9-4.png ] 臨床ナレッジAI「Cubec」を開発する株式会社Cubec（本社：大阪府吹田市、代表取締役CEO：奥井 伸輔）は、2025年12月4日に...
[画像: https://prtimes.jp/i/124652/6/resize/d124652-6-ae4e38298d8a616781ef-0.png ] 臨床ナレッジAI「Cubec」を開発する株式会社Cubec（本社：大阪府吹田市、代表取締役CEO：奥井 伸輔）は、京都キャピタルパ...
[画像1: https://prtimes.jp/i/124652/4/resize/d124652-4-50cff9910d0a18b51186-1.png ] 株式会社Cubec（本社：兵庫県神戸市東灘区、代表取締役CEO：奥井 伸輔）は、医師が抱える疑問に対し、信頼性の高い情報を...
[画像: https://prtimes.jp/i/124652/3/resize/d124652-3-2c0fd013495593c0dc10-0.jpg ] 写真提供：国立研究開発法人国立循環器病研究センター株式会社Cubec（以下、Cubec 本社：兵庫県神戸市東灘区、代表取締役...
Microsoft for Startups とは Microsoft for Startupsは、マイクロソフト社が世界140カ国以上にグローバル展開しているスタートアップ支援プログラムです。 革新的な技術やサービスを開発・提供をしているスタ...
[画像1: https://prtimes.jp/i/124652/1/resize/d124652-1-9de75484260b06329c8c-3.png ] 心不全患者が激増する「心不全パンデミック」 心不全は、心臓が全身に血液や酸素を送る「ポンプの機能」が働かなくな...
【Neoself Platform for Clinical Diagnostics and Drug Development】 AOI Bio leverages a newly discovered mechanism, coined Neoself, underlying autoimmune diseases to provide diagnostic services and to develop novel therapeutics. AOI Bio. currently offers clinical testing for the B2GPI Neoself Antibody in patients with unexplained recurrent pregnancy or implantation failures. 【Bioinformatics Analysis Platform for Drug Discovery】 AOI Bio employs advanced computational methods to identify novel biomarkers and drug candidates. By utilizing industry-leading solutions, such as quantum-optimized allosteric pocket identification, AOI Bio. drives its groundbreaking drug development efforts forward.
Our company is a R&D driven biotechnology firm specializing in therapeutic and diagnostic seeds for pancreatic cancer. We are developing antibodies that target pancreatic cancer stem cells and products utilizing unique antibodies derived from pancreatic cancer patients. Dedicated to bringing early diagnostic tools and effective treatments for pancreatic cancer to patients as quickly as possible, our goal is to ensure that our drug seeds and innovative technologies make a significant contribution to the treatment and early detection of pancreatic cancer.
A startup combining genome editing with smart land-based aquaculture to breed and produce high-value fish species using local resources. It aims to revitalize the fisheries industry and stabilize food supply, while contributing to lower environmental impact and regional revitalization.
BEL, Inc. is a deep-tech company specializing in materials science and surface engineering, focusing on the development and social implementation of advanced functional surfaces with antibacterial, antiviral, and anti-biofilm properties. The company integrates polymer science, additive manufacturing (3D printing), and surface microstructure control to create next-generation functional coatings for applications in medical devices, infrastructure, environmental systems, and marine environments. BEL actively promotes international collaboration with universities, research institutes, and industrial partners, aiming to advance materials innovation by integrating materials science with digital technologies such as data science and digital twin methodologies.
